An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate formed from a first material and a second material. At least one of the first and second materials includes a hemostatic agent. Kits, systems and methods are disclosed.

Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.

A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 μm to 2000 μm and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.

A composition for wound healing, comprising an amount of a macrophage proresolving polarizer, wherein the amount is effective to promote wound healing. The composition includes wherein the macrophage proresolving polarizer is lipin-1. The composition includes wherein the composition includes one, two, or three of IL-4, apoptotic cells (ACs), and AC derived lipids. The composition includes wherein the macrophage proresolving polarizer is a lipin-1 transcriptional coregulatory activity promoter. The composition includes, wherein the lipin-1 transcriptional coregulatory activity promoter is an inhibitor of lipin-1 macrophage pro-inflammatory responses enzymatic activity. A method for promoting wound healing, comprising contacting a wound on a skin of a mammal with the composition. A kit comprising one or more containers including the composition in sterile packaging. A wound healing device comprising a substrate and an amount of an amount of a macrophage proresolving polarizer, wherein the amount is effective to promote wound healing.

The invention relates to radiopaque liquid embolic composition comprising tetra iodo compound, 4,4-bis (4-hydroxy-3,5 diiodo phenyl) valeric acid (IBHV) of Formula I, covalently linked to ethylene vinyl alcohol copolymer (EVOH) and dissolved in a water miscible organic liquid.

Systems, methods and compositions relating to delivering synthetic polymer formulations to the body are described, which can be used by a range of medical personnel including those with minimal experience and training. Under some embodiments, the present invention relates to systems and devices for delivering polymer formulations to a body cavity (e.g. peritoneal cavity) to reduce or stop bleeding. Under some embodiments, an initial percutaneous access pathway is first formed using a delivery device with a probe and needle mechanism that automatically stops the advance of the device upon insertion into a body cavity or space, thus minimizing user error and improving patient safety. The hollow probe then allows transmission of polymer, mixed with gas and/or additional substances, from a holding chamber or canister to flow through the device and hollow probe into the patient's anatomic cavity or space of interest, stopping expansion when the device senses the appropriate pressure. Once reaching the body cavity, the polymer formulation functions to reduce and/or stop bleeding.

The present disclosure provides surgical implants that are useful for nipple-areola complex (NAC) or facial reconstruction in a subject, and methods for fabricating and using the same. The surgical implants of the present technology comprise minced or zested cartilage that is encaged by an external biocompatible scaffold.

Disclosed are solid and frozen haemostatic materials having a rod shape and suitable applicators and plungers for application of such dressings to wounded tissue wherein said dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques.